...
RAREMID

Ultragenyx Pharmaceutical Inc.

HealthcareBiotechnology
$23.39
$0.00(+1.52%)
52W$18.41
$43.22
FinancialsValuationvs AGIO
Updated Mar 3, 12:00 AM
RSI47
RS Rating15/99
Beta0.95
Volatility71%
F-Score4/9
Mkt Cap$2.3B
DOWNTREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

DOWNTREND

Ultragenyx Pharmaceutical Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 15), showing significant lag compared to the market leaders. Earnings contraction of 29% provides fundamental context to the price action. Investors should exercise caution due to high volatility (71% annualized), which requires wider risk management.

Relative Strength
15
out of 99
Lagging
Trend Score
0/4
Minervini Criteria
DOWNTREND
Risk (Beta)
0.95
vs S&P 500
MARKET
52W Position
20%
from 52W low
Lower Half
Trend & Momentum Analysis

Trend Template (Minervini)

DOWNTREND0/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$24.76
50 SMA > 100 SMA$29.19
100 SMA > 150 SMA$29.27
150 SMA > 200 SMA$30.63

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$23.14+1.09%ABOVE
50 SMA$24.76-5.53%BELOW
100 SMA$29.19-19.87%BELOW
150 SMA$29.27-20.10%BELOW
200 SMA$30.63-23.64%BELOW

Price Performance

1D+1.5%
1W+3.9%
1M-4.3%
3M-32.7%
6M-22.8%
YTD-0.9%
1Y-45.5%
3Y-19.3%
52-Week Trading Range20% from low
$23.39
52W Low$18.41
52W High$43.22

Technical Indicators

RSI (14)NEUTRAL
47.0
305070
VCP ScoreCOOL
3/10
Base depth: 91.8%

Risk Profile

Beta
0.95
52W Vol
71%
ATR
$1.29
Max DD (1Y)
-54%

Volume Analysis

Today
23
50D Avg
2.82M
Vol Ratio
0.00x
Liquidity
MODERATE

Earnings Momentum

Q4'24+9%
$-1.39
Q1'25+23%
$-1.57
Q2'25+23%
$-1.17
Q3'25-29%
$-1.81
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:+40.12%
3 Years:+16.82%
TTM:+20.63%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+8.19%

Stock Price CAGR

10 Years:-9.14%
5 Years:-30.33%
3 Years:-19.29%
1 Year:-45.50%

Return on Equity

10Y Avg:-84.4%
5Y Avg:-116.1%
3Y Avg:-172.0%
Last Year:-3588.3%

Key Metrics

Market Cap$2.3B
Gross Margin86.3%
Net Margin-1.0%
Piotroski F-Score4/9

More RARE Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

RARE vs AGIOAGIOVRTXASNDBBIO

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 15 meansRARE outperformed 15% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.95 means 5% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 4/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 3/10 with COOL status.

Frequently Asked Questions

Is RARE in an uptrend right now?

RARE has a trend score of 0/4 based on Minervini's Stage Analysis. Currently showing broken structure - 0 of 4 trend criteria are met.

Is RARE overbought or oversold?

RARE's RSI (14) is 47. The stock is in neutral territory, neither overbought nor oversold.

Is RARE outperforming the market?

RARE has a Relative Strength (RS) Rating of 15 out of 99. RARE is currently lagging the broader market.

Where is RARE in its 52-week range?

RARE is trading at $23.39, which is 54% of its 52-week high ($43.22) and 20% above its 52-week low ($18.41).

How volatile is RARE?

RARE has a Beta of 0.95 and 52-week volatility of 71%. It's less volatile than the S&P 500 - generally more stable.